Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Sarcoma 2Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Melanoma 2Brain Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 57Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 22Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 10Radiosurgery 10avelumab 9lifileucel 8dabrafenib 8Radiotherapy 8atezolizumab 7aldesleukin 7Paclitaxel 7Blood Specimen Collection 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cobimetinib × Dermatologic × 90 days × Clear all
NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Genentech, Inc.

Phase 1 Active not recruiting
65 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡